Anti-Fibrinolytic Drugs - India | Statista Market Forecast

In India, the revenue generated in the Anti-Fibrinolytic Drugs market is projected to reach US$165.90m in 2024.
Looking ahead, it is expected that the revenue will exhibit an annual growth rate (CAGR 2024-2029) of 5.41%, resulting in a market volume of US$215.80m by 2029.
When compared globally, United States is anticipated to generate the highest revenue of US$9.86bn in 2024.
India is experiencing a surge in demand for anti-fibrinolytic drugs due to the rising prevalence of cardiovascular diseases in the country.

Definition:
The Anti-Fibrinolytics market covers drugs which help blood to clot. They are used to treat and prevent bleeding episodes of patients with hemophilia. Moreover, anti-fibrinolytics are used before or during certain surgeries. In doing so, the usage of blood products, such as fresh frozen plasma, as well as the associated risks of infections and/or anaphylactic reactions can be avoided.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Roche, Takeda, Novo Nordisc, Sanofi, Bayer

Inhibitors of fibrinolysis
Drugs to treat hemophilia

Anti-coagulants
Anti-hypertensives
Wound care

The Anti-Fibrinolytic Drugs market in India has been exhibiting interesting trends in recent years.

Customer preferences: Anti-Fibrinolytic Drugs are commonly used to treat excessive bleeding in patients who have undergone surgery or have certain medical conditions. In India, there has been a growing demand for these drugs due to the increasing number of surgeries being performed and the rising prevalence of medical conditions such as hemophilia and liver cirrhosis. Additionally, the affordability of these drugs has also made them more accessible to a wider range of patients.

Trends in the market: One of the key trends in the Anti-Fibrinolytic Drugs market in India is the increasing adoption of generic drugs. This is largely due to the government's efforts to promote the use of generic drugs through initiatives such as the Jan Aushadhi Scheme. As a result, several Indian pharmaceutical companies have started manufacturing and selling generic versions of Anti-Fibrinolytic Drugs, which has led to increased competition and lower prices for consumers.Another trend in the market is the growing use of combination therapies. Anti-Fibrinolytic Drugs are often used in combination with other drugs to enhance their efficacy and reduce the risk of adverse effects. This trend is particularly evident in the treatment of hemophilia, where Anti-Fibrinolytic Drugs are often used in combination with clotting factor concentrates.

Local special circumstances: India has a large and growing pharmaceutical industry, which has been a key driver of growth in the Anti-Fibrinolytic Drugs market. Many Indian pharmaceutical companies have invested in research and development to develop new and innovative Anti-Fibrinolytic Drugs, which has helped to expand the market and provide patients with more treatment options.

Underlying macroeconomic factors: India's healthcare sector has been growing rapidly in recent years, driven by factors such as increasing disposable incomes, rising awareness about healthcare, and the government's focus on improving access to healthcare services. This has created a favorable environment for the Anti-Fibrinolytic Drugs market to grow and expand. Additionally, the government's push towards universal healthcare coverage through initiatives such as Ayushman Bharat is expected to further boost demand for Anti-Fibrinolytic Drugs in the coming years.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Bleeding disorders affect the clotting of blood and can result in excessive bleeding inside and outside of the body. Bleeding disorders are almost always inherited and common symptoms include easy bruising, frequent nosebleeds, heavy menstrual bleeding, and excessive bleeding from small cuts. Treatments vary depending on the type of disorder, but may include factor replacement therapy, iron supplementation, topical products or sprays, or blood transfusions. The most common types of bleeding disorders are hemophilia A and B and von Willebrand disease. In 2022, there were around 257,146 people worldwide who had been diagnosed with hemophilia and 100,505 who had been diagnosed with von Willebrand disease.